Back to Market返回行情

ANIP ANI Pharmaceuticals, Inc.

USHealthcare
$82.07-2.04%ClosedMarket Cap: $1.87B

As of 2026-07-10 16:00

Why ANIP matters now

ANI Pharmaceuticals, Inc. (ANIP) is a US stock in Healthcare. The latest InvestLog snapshot shows $82.07 with -2.04% on the session and $1.87B in market capitalization; recent performance reads 1-month -1.03% and YTD +0.70%.

The latest financial table shown here is Q1 2026, with revenue of $237.5M, net income of $29.5M, and EPS of $1.28. Investors can compare that operating picture with valuation signals such as P/E 23.20 and FCF yield 8.9%.

The latest indexable market news headline is "ANI Pharmaceuticals CFO Sells $240,000 in Stock After a 42% Cortrophin Surge" from The Motley Fool.

Additional event context on this page matters because analyst consensus is Buy with a median target of $124.00; recent insider activity includes Cook Meredith filing S-Sale. These signals are research inputs, not a recommendation.

Valuation

P/E (TTM)

23.20

PEG

0.05

P/B

2.96

P/S

1.96

EV/EBITDA

7.77

DCF Value

$1,055.37

FCF Yield

8.9%

Div Yield

0.0%

Margins & Returns

Gross Margin

65.9%

Operating Margin

13.4%

Net Margin

9.7%

ROE

17.3%

ROA

6.3%

ROIC

8.2%

Financials

PeriodRevenueNet IncomeEPS
Q1 2026$237.5M$29.5M$1.28
Q4 2025$247.1M$27.5M$1.17
FY 2025$883.4M$78.3M$3.32
Q3 2025$227.8M$24.1M$1.13

Analyst Ratings

Consensus

Buy

Target (Consensus)

$124.00

Target (Median)

$124.00

Target Range

$124.00 - $124.00

Strong Buy: 3Buy: 4Hold: 1Sell: 0Strong Sell: 0
GuggenheimBuy
2026-01-16
GuggenheimBuy
2025-11-10
Truist SecuritiesHold
2025-10-09
JP MorganOverweight
2025-09-24
HC Wainwright & Co.Buy
2025-09-17

Trading Activity

Insider Trades

Cook Meredithofficer: SR. VP, GENERAL COUNSEL & SEC.
Sell2026-06-15
HAUGHEY THOMASdirector
Sell2026-06-10
HAUGHEY THOMASdirector
Sell2026-06-10
Leonard Matthew Jdirector
Sell2026-06-10
Pera Antonio Rdirector
Sell2026-06-10

Company Info

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Country

US

Exchange

Beta

0.44

ANI Pharmaceuticals, Inc. operates as a biopharmaceutical firm, concentrating on the development, production, and commercialization of both proprietary (branded) and unbranded (generic) prescription medications across the United States and Canada. The company's primary focus areas include manufacturing controlled substances, treatments for oncology, hormones and steroids, injectable drugs, and various other pharmaceutical preparations. Its robust manufacturing capabilities encompass a range of dosage forms, such as oral solid products, semi-solids, liquid formulations, and topical agents, as well as highly potent compounds. Furthermore, ANI Pharmaceuticals provides contract development and manufacturing services to other pharmaceutical enterprises. The company distributes its products through a diverse network, which includes retail pharmacy chains, wholesalers, distributors, mail-order pharmacies, and group purchasing organizations. Incorporated in 2001, its corporate headquarters are situated in Baudette, Minnesota.